Nothing Special   »   [go: up one dir, main page]

CL2012003488A1 - Formulación intravenosa que comprende una solución acuosa de sulfobutil-eter-beta-ciclodextrina y amiodarona o una sal en proporción entre 2,7: 1 a 7:1; metodo de preparación; un artículo manufacturado, util en arritmias. - Google Patents

Formulación intravenosa que comprende una solución acuosa de sulfobutil-eter-beta-ciclodextrina y amiodarona o una sal en proporción entre 2,7: 1 a 7:1; metodo de preparación; un artículo manufacturado, util en arritmias.

Info

Publication number
CL2012003488A1
CL2012003488A1 CL2012003488A CL2012003488A CL2012003488A1 CL 2012003488 A1 CL2012003488 A1 CL 2012003488A1 CL 2012003488 A CL2012003488 A CL 2012003488A CL 2012003488 A CL2012003488 A CL 2012003488A CL 2012003488 A1 CL2012003488 A1 CL 2012003488A1
Authority
CL
Chile
Prior art keywords
amiodarone
arrhythmias
cyclodextrin
beta
salt
Prior art date
Application number
CL2012003488A
Other languages
English (en)
Inventor
Gerold L Mosher
Stephen Machatha
Daniel Cushing
Bushra Agha
Original Assignee
Baxter Healthcare Sa
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare Sa, Baxter Int filed Critical Baxter Healthcare Sa
Publication of CL2012003488A1 publication Critical patent/CL2012003488A1/es

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Formulación intravenosa que comprende una solución acuosa de sulfobutil-éter-beta-ciclodextrina y amiodarona o una sal en proporción entre 2,7: 1 a 7:1; método de preparación; un artículo manufacturado, útil en arritmias.
CL2012003488A 2010-06-11 2012-12-10 Formulación intravenosa que comprende una solución acuosa de sulfobutil-eter-beta-ciclodextrina y amiodarona o una sal en proporción entre 2,7: 1 a 7:1; metodo de preparación; un artículo manufacturado, util en arritmias. CL2012003488A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35392710P 2010-06-11 2010-06-11

Publications (1)

Publication Number Publication Date
CL2012003488A1 true CL2012003488A1 (es) 2013-04-01

Family

ID=44514348

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012003488A CL2012003488A1 (es) 2010-06-11 2012-12-10 Formulación intravenosa que comprende una solución acuosa de sulfobutil-eter-beta-ciclodextrina y amiodarona o una sal en proporción entre 2,7: 1 a 7:1; metodo de preparación; un artículo manufacturado, util en arritmias.

Country Status (9)

Country Link
US (1) US20120142768A1 (es)
EP (1) EP2579869A2 (es)
CN (1) CN103079559A (es)
AU (1) AU2011264919A1 (es)
BR (1) BR112012031504A2 (es)
CL (1) CL2012003488A1 (es)
MX (1) MX2012014479A (es)
WO (1) WO2011156481A2 (es)
ZA (1) ZA201300160B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150238483A1 (en) * 2012-09-19 2015-08-27 Centre National De La Recherche Scientifique- Cnrs Traitement des neuronopathies motrices
CN104887619A (zh) * 2014-03-04 2015-09-09 浙江普利药业有限公司 盐酸胺碘酮注射液及其制备方法
US9642828B2 (en) * 2014-09-23 2017-05-09 Sun Pharmaceutical Industries Limited Parenteral dosage form of amiodarone
CN105708835A (zh) * 2014-12-04 2016-06-29 辽宁药联制药有限公司 门冬氨酸钾联合胺碘酮治疗室性心律失常
WO2017149552A1 (en) * 2016-03-04 2017-09-08 Sun Pharmaceutical Industries Ltd. Parenteral dosage form of amiodarone
CN107753439A (zh) * 2016-08-22 2018-03-06 黑龙江迪龙制药有限公司 一种注射用盐酸胺碘酮及其制备方法
AR124867A1 (es) * 2021-02-15 2023-05-10 Sintetica S A Un medicamento en una bolsa de goteo intravenoso plegable lista para usar herméticamente sellada, método para hacer dicho medicamento y medicamento elaborado mediante dicho método
CN115969833A (zh) * 2023-01-03 2023-04-18 上海上药第一生化药业有限公司 胺碘酮药物组合物、注射液及其制备方法及含其的注射器

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692361A (en) 1984-09-28 1987-09-08 Baxter Travenol Laboratories, Inc. Film laminate with gas barrier for sterile flexible containers
US4686125A (en) 1984-09-28 1987-08-11 Baxter Travenol Laboratories, Inc. Film laminate for sterile flexible containers
US4779997A (en) 1987-04-27 1988-10-25 Baxter Travenol Laboratories, Inc. Closure for a port and closure assembly
WO1991004026A1 (en) * 1989-09-14 1991-04-04 Australian Commercial Research & Development Limited Drug delivery compositions
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5234949A (en) 1992-04-01 1993-08-10 Academic Pharmaceuticals, Inc. Parenteral solutions containing amiodarone in acetate buffer solution
US5849843A (en) 1993-11-16 1998-12-15 Baxter International Inc. Polymeric compositions for medical packaging and devices
US5998019A (en) 1993-11-16 1999-12-07 Baxter International Inc. Multi-layered polymer structure for medical products
FR2735978B1 (fr) 1995-06-30 1997-09-19 Sanofi Sa Composition pharmaceutique d'amiodarone pour administration parenterale
US6479541B1 (en) 2000-03-30 2002-11-12 Baxter International Amiodarone-containing parenteral administration
US20020143051A1 (en) 2001-03-29 2002-10-03 Doty Mark J. Premixed amiodarone parenteral solution and method for making the same
US6869939B2 (en) * 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin

Also Published As

Publication number Publication date
AU2011264919A1 (en) 2013-01-10
WO2011156481A2 (en) 2011-12-15
WO2011156481A3 (en) 2012-06-28
ZA201300160B (en) 2013-09-25
MX2012014479A (es) 2013-05-20
US20120142768A1 (en) 2012-06-07
EP2579869A2 (en) 2013-04-17
CN103079559A (zh) 2013-05-01
BR112012031504A2 (pt) 2016-11-08

Similar Documents

Publication Publication Date Title
CL2012003488A1 (es) Formulación intravenosa que comprende una solución acuosa de sulfobutil-eter-beta-ciclodextrina y amiodarona o una sal en proporción entre 2,7: 1 a 7:1; metodo de preparación; un artículo manufacturado, util en arritmias.
CL2015000574A1 (es) Formulaciones acuosas estables de adalimumab.
CL2016001547A1 (es) Composiciones para el cuidado oral
AR093645A1 (es) Una formulacion estabilizada de pemetrexed
AR081983A1 (es) Articulo de dosis unitaria soluble que comprende un polimero cationico
CL2013002599A1 (es) Composición que comprende una solución de ácido hipocloroso (hocl); proceso para preparar solución acuosa de hocl; uso como agente antimicrobiano, como agente de limpieza o esterilizador; material impregnado con la composición y uso para esterilizar objetos.
DOP2012000261A (es) Formulaciones de insulina de accion prolongada
AR065963A1 (es) Solucion acuosa de peroxido de hidrogeno, proceso para su preparacion y su uso
GT201200276A (es) Combinaciones de compuestos activos
MX2015013727A (es) Composicion para preparacion de uso externo con permeabilidad transdermica mejorada.
NZ606589A (en) 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
AR091465A1 (es) Una composicion farmaceutica que contiene acido nicotinico y/o nicotinamida y/o triptofano para influenciar positivamente la microbiota intestinal
MX2012003296A (es) Gotas oculares acuosas que contienen latanoprost, y metodo para inhibir la adsorcion de latanoprost a una resina.
BR112015000520A2 (pt) agente de espessamento estável com lipase
AR098168A1 (es) Formulación estable de insulina glulisina
CL2019001940A1 (es) Composiciones antimicrobianas y métodos de uso relacionados (divisional de solicitud 2519-2015).
EA201590617A1 (ru) Композиции алкилированного циклодекстрина и способы их получения и применения
BR112015023161A2 (pt) derivados de piridin-4-ila
TN2012000516A1 (en) Stable ready to use injectable paracetamol formulation
CL2012002781A1 (es) Producto que comprende un cuerpo de alimento compuesto por un componente de alimento y un componente de infusion que contiene mal todextrina en una concentracon de 5 a 65% con respecto al cuerpo del alimento; producto alimenticio; metodo para producir un cuerpo de alimento infusionado; y formulaciones de infusion.
MX2015006986A (es) Solucion de trombina y metodos de uso de esta.
CL2012003250A1 (es) Uso de un galactolipido en combinacion con acido ascorbico y/o un derivado del mismo que sirve para proteger una composicion contra la oxidacion; metodo para la preparacion de la composicion, composicion; y producto.
AR088398A1 (es) Preparacion de liberacion sostenida
CA2903759C (en) Concentrated aqueous azalide formulations
AR093813A1 (es) Composiciones en suspension de finafloxacina